Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review

被引：0
|
作者：
Wang, Wei [1 ,2 ]
Wu, Jiayi [1 ,3 ]
Chen, Keyu [1 ,3 ]
Wang, Xiaojia [1 ,4 ]
Shao, Xiying [1 ,4 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol Breast Canc, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Dept Clin Med, Wenzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Dept Clin Med, Hangzhou, Peoples R China
[4] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol Breast Canc, 1,Banshandong Rd, Hangzhou, Peoples R China
来源：
TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷
关键词：
breast cancer; palbociclib; CDK4/6; inhibitor; prognostic parameters;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
引用
收藏
页数：9
相关论文
共 50 条
  • [41] Efficacy and Safety of Palbociclib Plus Endocrine Therapy (ET) for HR+/HER2-Advanced Breast Cancer (ABC) in the Asian-Pacific (AP) Region
    Im, S-A
    Masuda, N.
    Im, Y-H
    Inoue, K.
    Kim, S-B
    Redfern, A.
    Lombard, J.
    Lu, D.
    Theall, K. P.
    Gauthier, E.
    Mukai, H.
    Ro, J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 62 - 62
  • [42] MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer
    Sledge, G. W.
    Toi, M.
    Neven, P.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Kaufman, P. A.
    Koh, H.
    Grischke, E-M.
    Conte, P. F.
    Lu, Y.
    Barriga, S.
    Hurt, K.
    Frenzel, M.
    Johnston, S. R. D.
    Llombart-Cussac, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 856 - 856
  • [43] Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer: final results from the POLARIS trial
    Tripathy, Debu
    Blum, Joanne L.
    Karuturi, Meghan S.
    Mccune, Steven
    Kurian, Sobha
    Moezi, Mehdi
    Anderson, Daniel
    Gauthier, Eric
    Zhang, Zhe
    Montelongo, Monica Z.
    Wang, Yao
    Rocque, Gabrielle B.
    ONCOLOGIST, 2024,
  • [44] Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2-Advanced Breast Cancer: A Nationwide Real-World Experience
    Boer, Katalin
    Rubovszky, Gabor
    Rokszin, Gyorgy
    Abonyi-Toth, Zsolt
    Foldesi, Csenge
    Dank, Magdolna
    ONCOTARGETS AND THERAPY, 2021, 14 : 3971 - 3981
  • [45] Efficacy and safety of sacituzumab govitecan in HR+/HER2-advanced breast cancer: A comprehensive systematic review and meta-analysis
    Qureshi, Zaheer
    Jamil, Abdur
    Altaf, Faryal
    Siddique, Rimsha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] UNDERSTANDING KEY SYMPTOMS, SIDE EFFECTS AND IMPACTS OF HR+ AND HER2-ADVANCED BREAST CANCER: LITERATURE REVIEW AND EXPERT INTERVIEWS
    Krohe, M.
    Tolley, C.
    Higgins, S.
    Cella, D.
    Revicki, D. A.
    Small, T.
    Tang, D.
    VALUE IN HEALTH, 2017, 20 (05) : A119 - A119
  • [47] Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [48] Cyclin-dependent kinases 4 and 6 inhibitors in HR+/HER2-advanced breast cancer.
    Wang, Ying
    Yu, Yunfang
    Liu, Shengbo
    Ou, Qiyun
    Yao, Herui
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Association of tumor DNA in circulation with clinical characteristics and treatment response in HR+/HER2-advanced breast cancer
    Solovieff, Nadia
    Su, Faye
    Leary, Rebecca
    Balbin, Alejandro
    Chakravartty, Arunava
    Lorenc, Karen Rodriguez
    Taran, Tetiana
    Babbar, Naveen
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [50] Capivasertib Maintains 1OL Benefit vs Placebo in HR+/HER2-Advanced Breast Cancer
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (02):
12345